Dr Reddy's Laboratories Ltd Stock News

Dr Reddy''s Laboratories jumped 5.74% to Rs 4,600 after the company announced that the Drugs Controller General of India (DCGI) has granted approval to the single-shot Sputnik Light vaccine for restricted use in emergency situation in India.

Drug major Dr Reddy''s Laboratories has submitted a proposal to the Drugs Controller General of India (DCGI) to register Sputnik Light vaccine as a booster dose against COVID-19, a top company official

"As regards to Sputnik, we are now ready with capacities in India. We are working actively with the Government of India for registering Sputnik Light as a vaccine and as a booster dose of Sputnik V," Dr Reddy''s Laboratories CEO Erez Israeli said in an analyst call.

India News: NEW DELHI: Drug major Dr Reddy''s Laboratories has submitted a proposal to the Drugs Controller General of India (DCGI) to register Sputnik Light vacci.

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is shaping up as we k

Pharmaceutical company Dr. Reddy's Laboratories Ltd. RDY has entered into a definitive agreement to acquire Nimbus Health GmbH, a medical cannabis-focused licensed pharmaceutical wholesaler from Germa

Dr Reddy''s Laboratories on Thursday said it has inked a pact to acquire Germany-based Nimbus Health GmbH. The drug major said it has entered into a definitive agreement to acquire the company which is a privately owned, licensed pharmaceutical wholesaler focusing on medical cannabis in Germany. Dr Reddy''s will acquire Nimbus Health for an upfront payment plus performance and milestone-based earn-outs over the next four years, the Hyderabad-based drug maker said in a regulatory filing. The company however did not share financial details. The acquisition will allow Dr Reddy''s to build on Nimbus Health''s strengths and introduce medical cannabis-based medicines as a promising treatment option for patients, it added. "Medical cannabis is increasingly used to address and treat high unmet medical needs, especially in pain management and CNS. Further, with numerous studies being conducted to leverage and introduce medical cannabis, we believe this is a must-be field for future healthcare

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2022 Results - Earnings Call Transcript

Stock market wrap up for January 27, 2022 The post Why Stocks Were Down Today: What To Know Now As Markets Sell-Off appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com

Pune, India, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The global OTC drugs market size is projected to grow from USD 157.0 billion in 2021 to USD 233.6 billion in 2028. The rising number of private label products is set to affect growth positively. In the U.S., shares of these products reached 31.0% in 2018 from 26.0% in 2009. Also, numerous companies are collaborating with e-commerce platforms to launch their products on their platforms. Amazon.com, Inc., for instance, introduced Perrigo''s over-the-counter healthcare products in February 2018. Fortune Business Insights mentioned this in a published report, titled, " OTC Drugs Market, 2021-2028 ." The report further states that the market stood at USD 148.0 billion in 2020. It is set to showcase a CAGR of 5.8% in the forecast period during 2021-2028. Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/over-the-counter-otc-drugs-market-105433 Dr Reddy''s Laboratories Unveils Famotidine Tablets in U.S. to Treat GERD In October 2020, Dr Reddy''s Laboratories, a multinational pharmaceutical company headquartered in India introduced the Famotidine tablet, an OTC drug for the treatment of gastroesophageal reflux disease (GERD) in the U.S.

Aurobindo Pharma launches Covid-19 drug Molnupiravir in India.Earlier this week, the pharmaceutical major Dr Reddy''s Laboratories Ltd said it will soon launch the generic version of Merck''s antiviral Covid-19 pill, Molnupiravir

India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, reported Reuters. A company spokesperson said Reddy's